The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Cell Lines for the Production of Recombinant Adeno-Associated Virus
Abstract
Adeno-associated virus (AAV) is a replication-defective parvovirus that is being developed as a vector for human gene transfer. However, a major obstacle to commonplace usage of AAV vectors is the production of recombinant virions (rAAV) in sufficient quantities for not only human trials, but also for preclinical studies of basic biology, toxicology, and efficacy. Unfortunately, current methods for large-scale production are cumbersome and expensive. We have developed a simplified method for generating rAAV by establishing neomycin-resistant cell lines containing copies of the AAV rep-cap genes and a rAAV vector. After infection with adenovirus, these cell lines were shown to produce infectious rAAV in relatively high titer. This method eliminates the need for exogenous DNA transfection and scale-up procedures are limited only by the normal constraints of growing cells in culture. This paper describes a simplified method for the production of recombinant adeno-associated virus (AAV) that involves the establishment of stable cell lines containing copies of the AAV rep and cap genes and a rAAV vector genome. In this system, rAAV is produced by merely infecting the cell line with adenovirus. Transfection of exogenous DNA is not required, and thus, large-scale production strategies become feasible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selective extraction of polyoma DNA from infected mouse cell cultures
Hirt, B. (1967) · Journal of Molecular Biology · doi:10.1016/0022-2836(67)90307-5 · Cited by 5,146
Shi, Y., Seto, E., Chang, L.-S., & Shenk, T. (1991) · Cell · doi:10.1016/0092-8674(91)90189-6 · Cited by 1,035
Kaplitt, M. G., Leone, P., Samulski, R. J., Xiao, X., Pfaff, D. W., O'Malley, K. L., & During, M. J. (1994) · Nature Genetics · doi:10.1038/ng1094-148 · Cited by 1,031
Adenovirus-Associated Defective Virus Particles
Atchison, R. W., Casto, B. C., & Hammon, W. M. (1965) · Science · doi:10.1126/science.149.3685.754 · Cited by 1,004
Site-specific integration by adeno-associated virus.
Kotin, R. M., Siniscalco, M., Samulski, R. J., Zhu, X. D., Hunter, L., Laughlin, C. A., McLaughlin, S., Muzyczka, N., Rocchi, M., & Berns, K. I. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.6.2211 · Cited by 868
Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells
Muzyczka, N. (1992) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-75608-5_5 · Cited by 754
Manipulation of Adenovirus Vectors
Graham, F. L., & Prevec, L. (2003) · Gene Transfer and Expression Protocols · doi:10.1385/0-89603-178-0:109 · Cited by 752
Samulski, R. J., Chang, L. S., & Shenk, T. (1989) · Journal of Virology · doi:10.1128/jvi.63.9.3822-3828.1989 · Cited by 743
Flotte, T. R., Afione, S. A., Conrad, C., McGrath, S. A., Solow, R., Oka, H., Zeitlin, P. L., Guggino, W. B., & Carter, B. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10613 · Cited by 490
Hermonat, P. L., & Muzyczka, N. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.20.6466 · Cited by 481
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Zolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R. J., & Muzyczka, N. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300938 · Cited by 1,312
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“4,15 Vectors produced with other technologies, such as baculovirus expression systems 113 or with the use of live helper virus, 114 have also been used in human trials but were administered intramuscularly, 16 or subretinally, 5 or at lower doses than in the hemophilia studies.”
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Novel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors
Grimm, D., Kern, A., Rittner, K., & Kleinschmidt, J. A. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.18-2745 · Cited by 696
GENE THERAPY: Twenty-First Century Medicine
Verma, I. M., & Weitzman, M. D. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.050304.091637 · Cited by 616
Production and characterization of adeno-associated viral vectors
Grieger, J. C., Choi, V. W., & Samulski, R. J. (2006) · Nature Protocols · doi:10.1038/nprot.2006.207 · Cited by 581
Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors
Zolotukhin, S., Potter, M., Zolotukhin, I., Sakai, Y., Loiler, S., Fraites, T. J., Chiodo, V. A., Phillipsberg, T., Muzyczka, N., Hauswirth, W. W., et al. (2002) · Methods · doi:10.1016/s1046-2023(02)00220-7 · Cited by 565
Gene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541
Insect Cells as a Factory to Produce Adeno-Associated Virus Type 2 Vectors
Urabe, M., Ding, C., & Kotin, R. M. (2002) · Human Gene Therapy · doi:10.1089/10430340260355347 · Cited by 457
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Keeler, A. M., & Flotte, T. R. (2019) · Annual Review of Virology · doi:10.1146/annurev-virology-092818-015530 · Cited by 322
Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
Clark, K. R., Liu, X., Mcgrath, J. P., & Johnson, P. R. (1999) · Human Gene Therapy · doi:10.1089/10430349950018427 · Cited by 305
Self-citationGenetic Fate of Recombinant Adeno-Associated Virus Vector Genomes in Muscle
Schnepp, B. C., Clark, K. R., Klemanski, D. L., Pacak, C. A., & Johnson, P. R. (2003) · Journal of Virology · doi:10.1128/jvi.77.6.3495-3504.2003 · Cited by 262
Self-citationWright, J. (2014) · Biomedicines · doi:10.3390/biomedicines2010080 · Cited by 219
“For example, AAV vector production systems based on human cell lines [21–24] and insect cell lines [25–27] result in qualitative differences in the nature of residual host cell proteins and nucleic acids, with corresponding differences in the risk of potential immunotoxicity”
BackgroundManufacturing and characterizing AAV-based vectors for use in clinical studies
Wright, J. F. (2008) · Gene Therapy · doi:10.1038/gt.2008.65 · Cited by 205
Pharmacology of Recombinant Adeno-associated Virus Production
Penaud-Budloo, M., François, A., Clément, N., & Ayuso, E. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.002 · Cited by 177
Treatment of human disease by adeno-associated viral gene transfer
Warrington, K. H., & Herzog, R. W. (2006) · Human Genetics · doi:10.1007/s00439-006-0165-6 · Cited by 155
“Alternative production systems are based on rep/cap expressing producer cells (derived from HELA cells), on insect cells infected with baculovirus, or on use of Herpes helper virus (Clark et al. 1995; Conway et al. 1997, 1999; Urabe et al. 2002).”
Recombinant Adeno-Associated Viral Vectors Mediate Long-Term Transgene Expression in Muscle
Clark, K. R., Sferra, T. J., & Johnson, P. R. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.6-659 · Cited by 153
Self-citationBurnham, B., Nass, S., Kong, E., Mattingly, M., Woodcock, D., Song, A., Wadsworth, S., Cheng, S. H., Scaria, A., & O'Riordan, C. R. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.048 · Cited by 150
“As adaptation of the transient transfection protocol to a manufacturing process is challenging, alternate scalable production methods such as those using baculovirus, 25–28 herpes simplex HSV, 29,30 or packaging/producer cell lines 31–38 are being considered.”
Transient transfection methods for clinical adeno-associated viral vector production
Wright, J. F. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.064 · Cited by 131
Lewis, A. D., Chen, R., Montefiori, D. C., Johnson, P. R., & Clark, K. R. (2002) · Journal of Virology · doi:10.1128/jvi.76.17.8769-8775.2002 · Cited by 124
Self-citationManufacturing of recombinant adeno-associated viruses using mammalian expression platforms
Robert, M., Chahal, P. S., Audy, A., Kamen, A., Gilbert, R., & Gaillet, B. (2017) · Biotechnology Journal · doi:10.1002/biot.201600193 · Cited by 89
Grieger, J. C., Johnson, J. S., Gurda-Whitaker, B., Agbandje-McKenna, M., & Samulski, R. J. (2007) · Journal of Virology · doi:10.1128/jvi.00580-07 · Cited by 83
“(11, 12), a HeLa cell line with the wt AAV2 coding region integrated with a”
BackgroundFrançois, A., Bouzelha, M., Lecomte, E., Broucque, F., Penaud-Budloo, M., Adjali, O., Moullier, P., Blouin, V., & Ayuso, E. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.07.004 · Cited by 50
Vector characterization methods for quality control testing of recombinant adeno-associated viruses
Wright, J. F., & Zelenaia, O. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61779-095-9_11 · Cited by 34
Tang, Y., Yan, Z., Lin, S., Huntemann, E. D., Feng, Z., Park, S.-Y., Sun, X., Yuen, E., & Engelhardt, J. F. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.09.008 · Cited by 21
Gurazada, S. G. R., Kennedy, H. M., Braatz, R. D., Mehrman, S. J., Polson, S. W., & Rombel, I. T. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108506 · Cited by 9
de Oliveira, A. P., & Fraefel, C. (2010) · The Open Virology Journal · doi:10.2174/1874357901004030109 · Cited by 3
Metadata
- Authors
- Clark, K. R., Voulgaropoulou, F., Fraley, D. M., & Johnson, P. R.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 1995-10
- Volume
- 6
- Issue
- 10
- Pages
- 1329-1341
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2068065419
- Cited by
- 257
- References
- 46
- FWCI
- 6.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.